```
                10          20          30          40
2C4     DTVMTQSHKIMSTSVGDRVSITC [KASQDVSIGVA] WYQQRP
         **    **** *       *                    *
574     DIQMTQSPSSLSASVGDRVTITC [KASQDVSIGVA] WYQQKP
        .                       *   ** ***
hum xI  DIQMTQSPSSLSASVGDRVTITC [RASQSISNYLA] WYQQKP

                50          60          70          80
2C4     GQSPKLLIY [SASYRYT] GVPDRFTGSGSGTDFTFTISSVQA
          **                  *  *        *    *
574     GKAPKLLIY [SASYRYT] GVPSRFSGSGSGTDFTLTISSLQP
                   * *****
hum xI  GKAPKLLIY [AASSLES] GVPSRFSGSGSGTDFTLTISSLQP

                90         100
2C4     EDLAVYYC [QQYYIYPYT] FGGGTKLEIK (SEQ ID NO: 1)
           * *                 * *
574     EDFATYYC [QQYYIYPYT] FGQGTKVEIK (SEQ ID NO: 3)
                    *** *
hum xI  EDFATYYC [QQYNSLPWT] FGQGTKVEIK (SEQ ID NO: 5)
```

FIG. 1A: VARIABLE LIGHT

```
                10          20          30          40
2C4     EVQLQQSGPELVKPGTSVKISCKAS [GFTFTDYTMD] WVKQS
          **  **   *   * *** *                    * *
574     EVQLVESGGGLVQPGGSLRLSCAAS [GFTFTDYTMD] WVRQA
                                     **  *  *
hum III EVQLVESGGGLVQPGGSLRLSCAAS [GFTFSSYAMS] WVRQA

                50 a        60          70          80
2C4     HGKSLEWIG [DVNPNSGGSIYNQRFKG] KASLTVDRSSRIVYM
          *   *   **                    *** *    **** *
574     PGKGLEWVA [DVNPNSGGSIYNQRFKG] RFTLSVDRSKNTLYL
                   ****** *** * ****      * * *
hum III PGKGLEWVA [VISGDGGSTYYADSVKG] RFTISRDNSKNTLYL

              abc       90          100ab       110
2C4     ELRSLTFEDTAVYYCAR [NLGPSFYFDY] WGQGTTLTVSS (SEQ ID NO: 2)
        ***  **                                 **
574     QMNSLRAEDTAVYYCAR [NLGPSFYFDY] WGQGTLVTVSS (SEQ ID NO: 4)
                          ********
hum xI  QMNSLRAEDTAVYYCAR [GRVGYSLYDY] WGQGTLVTVSS (SEQ ID NO: 6)
```

FIG. 1B: VARIABLE HEAVY

FIG. 2A





FIG. 2B



IP: αHER2
WB: αHER3



HER2 containing dimers in protein extracts from Oncotest NSCLC xenograft explants
Hans-Joachim Mueller, Roche
LXFE 211
LXFA 289
LXFA 297
LXFE 397
LXFA 526
LXFL 529
LXFA 629
LXFA 1041
LXFL 1072
HER 1
HER 1/2
HER 3
HER 2/3
1) Blotting with anti-HER1
2) IP anti HER2
Blotting with anti-HER1
1) Blotting with anti-HER3
4) IP anti HER2
Blotting with anti-HER3
HER2/HER1 dimers and HER2/HER3 dimers are elevated in the rhuMAb 2C4 responsive versus rhuMAb 2C4 non-responsive NSCLC xenografts.

FIG. 3



HER2 expression/activation in protein extracts from Oncotest NSCLC xenograft explants
HER 2
Phospho HER 2 (phospho-HER1 phospho-HER3)
LXFL 1072
LXFA 1041
LXFA 629
LXFL 529
LXFA 526
LXFE 397
LXFA 297
LXFA 289
LXFE 211
IP with anti-HER2 followed by:
1) Blotting with anti-HER2
2) Blotting with anti-PY

FIG. 4